(1) Improved rating elevates Hikma to global leadership position LONDON, Jan. 13, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, has received an 'A-' rating from the CDP 2020 Global Climate Change Report, improving on the Group's previous score and elevating Hikma to CDP's Leadership Band of companies implementing current best practices. CDP is an independent, not-for-profit organisation aimed at enabling companies to progress towards environmental stewardship through benchmarking and comparison with peers. In the 2020 report, Hikma received an "A" rating in five separate categories ranked by CDP, including for its emission reduction initiatives, its scope 1 and 2 emissions (greenhouse gas emissions from direct fuel usage and electricity consumption), its governance and risk management processes, and its business strategy and financial planning. Hikma's performance - with at or above average marks in every category evaluated - exceeded the global average, the European regional average, and the biotech and pharma sector average.